Serina Therapeutics Advances Parkinson’s Drug Trial to Cohort 2 After Positive Early Data — Serina Therapeutics, Inc.

Event summary

Serina Therapeutics' SER-252 Phase 1b trial for advanced Parkinson’s disease advances to Cohort 2 after positive Cohort 1 safety and tolerability data.
Blinded Cohort 1 observations showed sustained pharmacokinetic profile and motor function improvements in individual patients.
Topline data from the single-ascending-dose portion of the study expected in the first half of 2027.
The study is a randomized, double-blind, placebo-controlled trial with exploratory clinical measures including MDS-UPDRS motor scores.
SER-252 is designed to provide sustained apomorphine exposure via subcutaneous injection, aiming to reduce treatment burden.

The big picture

Serina Therapeutics' advancement to Cohort 2 in the SER-252 trial underscores the potential of its POZ Platform technology to deliver sustained dopaminergic stimulation for advanced Parkinson’s patients. The positive early data aligns with broader industry trends toward developing more convenient and effective treatments for neurodegenerative diseases. The success of SER-252 could differentiate it from existing therapies, addressing a significant unmet need in the management of motor fluctuations in Parkinson’s disease.

What we're watching

Clinical Efficacy: Whether the sustained pharmacokinetic profile and motor function improvements observed in Cohort 1 will translate into consistent efficacy across higher dose levels.
Regulatory Pathway: The pace at which Serina Therapeutics can advance SER-252 through the regulatory approval process, given the positive early data.
Market Differentiation: How SER-252's long-acting formulation of apomorphine will position it against existing continuous infusion approaches for advanced Parkinson’s disease.